A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer.

@article{Ferrarotto2012AMM,
  title={A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer.},
  author={Renata Ferrarotto and Karime Kalil Machado and Milena Perez Mak and Neeraj Shah and Tiago Kenji Takahashi and Frederico Perego Costa and Michael J Overman and Scott Kopetz and Paulo Marcelo Gehm Hoff},
  journal={European journal of cancer},
  year={2012},
  volume={48 6},
  pages={820-6}
}
BACKGROUND A considerable number of metastatic colorectal cancer (mCRC) patients who progress on standard treatment with 5-fluorouracil (5FU), oxaliplatin, irinotecan and monoclonal antibodies, still have adequate performance status and desire further treatment. Mitomycin C (MMC) has been widely used in this context, and despite good tolerability, there are doubts regarding its true benefit. METHODS In order to assess the activity of MMC in the refractory mCRC setting, we retrospectively… CONTINUE READING

Citations

Publications citing this paper.

Similar Papers

Loading similar papers…